DeepMed Research

Centro Nacional de Investigaciones Oncologicas CARLOS III

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

High Definition Medicine for Solid Tumors Oncology

Recruiting

Conditions: Metastatic Solid Tumor
Advanced Cancer

Interventions: Device: Wearable

First Posted Date: 2024-09-11

Last Posted Date: 2024-09-19

Lead Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III

Target Recruit Count: 300

Registration Number: NCT06590506

Locations: 🇪🇸
Hospital Universitario A Coruña, La Coruña, A Coruña/ Galicia, Spain
🇪🇸
Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain
🇪🇸
Hospital Son Espases, Palma De Mallorca, Mallorca / Baleares, Spain

and more 6 locations

Prospective Multicentre Cohort Study PROREPAIR-B (mCRPC)

Completed

Conditions: Prostate Cancer

First Posted Date: 2017-03-09

Last Posted Date: 2019-02-04

Lead Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III

Target Recruit Count: 408

Registration Number: NCT03075735

SWITCH: Study of the Prednisone to Dexamethasone Change in mCRPC Patients Treated With Abiraterone

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Steroids switch

First Posted Date: 2016-10-10

Last Posted Date: 2017-01-27

Lead Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III

Target Recruit Count: 26

Registration Number: NCT02928432

Locations: 🇪🇸
Spanish National Cancer Research Centre (CNIO), Madrid, Spain

PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Radium-223.

Conditions: Advanced Prostate Cancer
Radium 223
Castration Resistant

Interventions: Drug: Radium 223 55mBq/Kg every 4 weeks intravenously

First Posted Date: 2016-10-06

Last Posted Date: 2020-01-27

Lead Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III

Target Recruit Count: 161

Registration Number: NCT02925702

Locations: 🇪🇸
Hospital Universitario Reina Sofia, Cordoba, Spain
🇪🇸
Hospital Universitario de Elche, Elche, Alicante, Spain
🇪🇸
Hospital San Llatzer, Palma de Mallorca, Islas Baleares, Spain

and more 60 locations

PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in mCRPC Patients Treated With Enzalutamide.

Conditions: Castration Resistant
Advanced Prostate Cancer
Enzalutamide

First Posted Date: 2016-10-04

Last Posted Date: 2020-01-27

Lead Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III

Target Recruit Count: 187

Registration Number: NCT02922218

Locations: 🇪🇸
Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
🇪🇸
Hospital Universitario Vall D'Hebron, Barcelona, Spain
🇪🇸
ICO L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain

and more 23 locations

ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism

Early Phase 1

Completed

Conditions: Early-Stage Breast Carcinoma
Breast Cancer
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Interventions: Drug: ME-344
Other: Normal saline
Drug: Bevacizumab

First Posted Date: 2016-06-21

Last Posted Date: 2019-07-23

Lead Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III

Target Recruit Count: 40

Registration Number: NCT02806817

Locations: 🇪🇸
Hospital Ramón y Cajal, Madrid, Spain
🇪🇸
H. Arnau de Vilanova Lleida, Lleida, Spain
🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain

and more 2 locations

Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer

Early Phase 1

Completed

Conditions: Bevacizumab-alone Maintenance Treatment Progression
Metastatic Breast Cancer

Interventions: Drug: Durvalumab
Drug: Bevacizumab

First Posted Date: 2016-06-16

Last Posted Date: 2020-06-19

Lead Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III

Target Recruit Count: 25

Registration Number: NCT02802098

Locations: 🇪🇸
H. Arnau de Vilanova Lleida, Lleida, Spain
🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸
Hospital Ramón y Cajal, Madrid, Spain

and more 3 locations

PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate.

Conditions: Advanced Prostate Cancer
Abiraterone ACetate

First Posted Date: 2016-06-01

Last Posted Date: 2020-01-27

Lead Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III

Target Recruit Count: 220

Registration Number: NCT02787837

Locations: 🇪🇸
Hospital Madrid Sanchinarro, Madrid, Spain
🇪🇸
Anatomical Pathology PROCURE-PROSABI, Malaga, Spain
🇪🇸
Centro Integral Oncologico Clara Campal, Madrid, Spain

and more 21 locations

Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Nintedanib
Drug: Letrozole

First Posted Date: 2015-12-02

Last Posted Date: 2019-07-23

Lead Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III

Target Recruit Count: 25

Registration Number: NCT02619162

Locations: 🇪🇸
Hospital de La Princesa, Madrid, Spain
🇪🇸
Clínica Quirón, Madrid, Spain
🇪🇸
Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain

PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.

Conditions: Advanced Prostate Cancer
Cabazitaxel
Docetaxel

First Posted Date: 2015-02-13

Last Posted Date: 2020-01-27

Lead Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III

Target Recruit Count: 402

Registration Number: NCT02362620

Locations: 🇪🇸
Hospital Universitario de Santiago, Santiago de Compostela, A Coruña, Spain
🇪🇸
ICO L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
🇪🇸
Hospital Althaia Manresa, Manresa, Barcelona, Spain

and more 22 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy